Adjuvanted human papillomavirus vaccine recombinant nonavalent - Merck

Drug Profile

Adjuvanted human papillomavirus vaccine recombinant nonavalent - Merck

Alternative Names: 9-valent HPV L1 vaccine adjuvanted with AAHS and ISCOMATRIX™ - Merck; 9-valent HPV L1 VLP-AAHS/IMX vaccine - Merck; Adjuvanted HPV L1 VLP 9-valent vaccine - Merck; Adjuvanted human papillomavirus L1 virus-like-particle nonavalent vaccine - Merck; Broad-spectrum human papillomavirus vaccine - Merck; V-505

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Cancer vaccines; Papillomavirus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cervical cancer; Human papillomavirus infections

Most Recent Events

  • 24 Jun 2011 Merck & Co completes a phase IIa trial in Cervical cancer and Human papillomavirus infections in Australia and New Zealand (NCT00520598)
  • 22 Mar 2010 Phase-II development is ongoing in Australia and New Zealand
  • 25 Oct 2007 Phase-II clinical trials in Cervical cancer in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top